ArticleMolecular medicine reports2025
Recombinant human collagen XVII protects skin basement membrane integrity by inhibiting the MAPK and Wnt signaling pathways.
Article in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Therapeutic potential of recombinant human collagen XVII in blue light-induced skin photoaging: preserving epidermal-dermal structural integrity and functional homeostasis.Frontiers in bioengineering and biotechnology · 2026Article
- Nanocomposite-loaded hybrid microneedles reshape dermal microenvironment through senolytic delivery and collagen XVII-mediated barrier repair.Materials today. Bio · 2025Article
- FREM1 serves as a novel therapeutic target in breast cancer through basement membrane-based prognostic modeling with integrated bioinformatics and experimental validation.Discover oncology · 2025Article
- Recombinant humanized collagen combined with nicotinamide increases the expression level of rat basement membrane proteins and promotes hair growth.Frontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collagen XVII is a key component linking the cytoskeleton to the basement membrane, serving an essential role in maintaining skin integrity. With the advancement of synthetic biology, recombinant human collagen XVII (RHCXVII) has emerged as a promising novel collagen material. The present study aimed to elucidate the efficacy and mechanisms of action of RHCXVII in protecting skin basement membrane integrity. A skin injury model was established using ultraviolet B (UVB) irradiation on human HaCaT keratinocytes treated with RHCXVII. The effects of RHCXVII on cell migration and adhesion were assessed using wound healing assay and hematoxylin and eosin staining, respectively. The expression of key extracellular matrix (ECM) components such as collagen IV, collagen VII, laminin 332 and integrin α6 (ITGA6) were quantified using reverse transcription‑quantitative PCR and western blotting. The mechanism of action of RHCXVII in protecting skin basement membrane integrity was investigated using a phosphorylated‑antibody array and verified by western blotting. RHCXVII significantly increased the migration and adhesion of UVB‑irradiated HaCaT cells (P<0.01). Additionally, RHCXVII significantly upregulated expression levels of collagen type IV α1 chain, collagen type VII α1 chain, laminin subunit β3 and ITGA6 in UVB‑irradiated HaCaT cells (P<0.05). RHCXVII significantly inhibited the phosphorylation of p38 and c‑Jun in the MAPK and Wnt signaling pathways (P<0.01). In conclusion, RHCXVII protected skin basement membrane integrity by enhancing migration and adhesion of keratinocytes, upregulating key ECM components and inhibiting protein phosphorylation in MAPK and Wnt pathways. The present study enhanced the current understanding of RHCXVII as a protector of skin basement membrane integrity. Furthermore, the present study highlighted clinical implications and the broad therapeutic potential of RHCXVII in both medical and cosmetic application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.